Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
Formulation & Drug Delivery Webinars
Patient-Centric Drug Development
Wed, Feb 19, 2020 10:30 AM - 11:30 AM GMT
Presented by Sven Steggemann, Professor for Patient Centric Drug Development and Manufacturing, Graz University of Technology
In this free interactive webinar we’ll be hearing from Sven Stegemann, Graz University of Technology as he outlines deep insights into the current challenges and solutions in drug development for specific patient populations – as a pharmaceutical development professional, this is one webinar you won’t want to miss!
Our free webinar is for professionals involved in Formulation and drug delivery interested in hearing about innovative drug solubility. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Sven’s experience spans all stages of drug development and manufacturing, from early development through commercial manufacturing. His holistic perspective allows him to identify evolving challenges and trends to address them through pragmatic and meaningful solutions that benefit customers and patients.
For more than a decade, Sven’s expertise has been on understanding patient’s views of drug products and how they interface with them, taking into account multi-morbid patients with complex therapies, to determine how their needs can be included into drug product design and development.This led him to found the Geriatric Medicine Society e.V. in 2009, a multidisciplinary network that aims to facilitate the development of age-appropriate medicines that older patients can easily and safely take. Sven also serves in various organizations as chairman or committee member to progress pharmaceutical sciences.In 2014, Sven established a focus group on patient centric drug development through the American Association of Pharmaceutical Scientists (AAPS). He currently chairs the group.
As endowed professor for Patient Centric Drug Product Design and Manufacturing at the Graz University of Technology, Sven trains the next generation of pharmaceutical scientists. This is integral to improving the quality of life of patients in the future.
Inhalation & Respiratory Drug Delivery Webinars
Inhaled Targeted-Inhibition Of Galectin-3 Dose Dependently Blocks Plasma Biomarkers In Patients With Idiopathic Pulmonary Fibrosis
Tue, Mar 3, 2020 2:00 PM - 3:00 PM GMT
Presented by Tariq Sethi, Co-Founder, Galacto Biotech and Former Chief Scientist Vice President Clinical Development Unit, AstraZeneca
Hosted by Tariq Sethi, Co-Founder, Galacto Biotech and Former Chief Scientist Vice President Clinical Development Unit, AstraZeneca
- Galectin-3 is a key regulator of fibrosis
- TD-139 is a specific Galectin-3 inhibitor formulated for inhaled treatment
- TD139 is safe and well tolerated in man
- TD-139 demonstrated dose dependent target engagement
- TD-139 specifically decreases in plasma biomarkers associated with IPF progression
- Suggesting inhaled TD-139 is a potential novel therapy for IPF
Our complimentary webinar is for respiratory and inhalation experts interested in learning more about the latest innovations in inhaled therapies. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Professor Tariq Sethi is Chief Physician Scientist, Vice President AstraZeneca and Emeritus Professor of Respiratory Medicine Kings College London. He was previous head of the Respiratory Immunology Autoimmunity Translational Medicine Unit. Prior to joining AZ he was Head of Respiratory Medicine at Guy’s, St. Thomas’ and King’s College Hospital NHS Foundation Trusts and Professor of Respiratory Medicine King’s College London and formally Professor at the University of Edinburgh. He was educated at Cambridge and London Universities followed by hospital jobs in London. He did a Ph.D at the Imperial Cancer Research Fund London, was an MRC Travelling Fellow at the Scripps Research Institute California and a Wellcome Trust Senior Research Leave Fellow in Edinburgh. His research interests focus on the interaction between inflammation and lung cancer, Prof. Sethi continues on the editorial board of THORAX and was formally a member of the Population Systems Medicine Board Medical Research Council UK, Chair of Asthma (UK) and member of the British Lung Foundation Scientific Committees. He is also a Co-Founder of Galecto Biotech